Related Experiment Video
Updated: Dec 9, 2025

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
Published on: August 11, 2023
Early and Supernormal Vascular Aging: Clinical Characteristics and Association With Incident Cardiovascular Events
Rosa Maria Bruno1, Peter M Nilsson2, Gunnar Engström2
1From the INSERM, U970, Paris Cardiovascular Research Center-PARCC, France (R.M.B., J.-P.E., P.B., S.L.).
Insights
Individuals with supernormal vascular aging, characterized by a younger vascular age than chronological age, experience fewer cardiovascular events. This finding validates the concept and may reveal protective pathways for healthy aging.
Area of Science:
- Cardiovascular Health
- Aging Research
- Vascular Biology
Background:
- Pulse wave velocity (PWV) is a key indicator of vascular aging.
- PWV may also identify individuals with 'supernormal' vascular aging.
- Defining and validating supernormal vascular aging is crucial for understanding cardiovascular risk.
Purpose of the Study:
- To test the hypothesis that a large difference between chronological and vascular age (Δ-age) is linked to lower cardiovascular event rates.
- To define and validate the concept of supernormal vascular aging using prospective data.
- To investigate the association between vascular aging categories and cardiovascular event risk.
Main Methods:
- Vascular age was calculated using a regression model incorporating PWV and cardiovascular risk factors.
- Δ-age was computed as chronological age minus vascular age.
- Cardiovascular event risk was analyzed in the Malmö Diet and Cancer Study cohort based on Δ-age percentiles.
Main Results:
- A significant inverse association was found between Δ-age and cardiovascular events (P<0.01).
- Supernormal vascular aging (Δ-age > 6.8 years) showed a reduced risk of cardiovascular events (HR, 0.59).
- Early vascular aging (Δ-age < -5.7 years) demonstrated an increased risk (HR, 2.70), particularly for coronary events.
Conclusions:
- This study provides the first prospective validation of the clinical significance of supernormal vascular aging.
- The findings support the concept that a younger vascular age confers protection against cardiovascular events.
- Further research into supernormal vascular aging may uncover novel protective mechanisms and preventive strategies.
Abstract:
Pulse wave velocity is an established marker of early vascular aging but may also help identifying individuals with supernormal vascular aging. We tested the hypothesis that individuals with the largest difference (Δ-age) between chronological and vascular age show the lowest rate of cardiovascular events and may thus be defined as supernormal vascular aging. Vascular age was defined as the predicted age in the best fitting multivariable regression model including classical risk factors and treatment and pulse wave velocity, in a subset of the Reference Values for Arterial Stiffness Collaboration Database (n=3347). Δ-age was then calculated as chronological age minus vascular age, and the 10th and 90th percentiles were used to define early (Δ-age<-5.7 years), normal (Δ-age -5.7 to 6.8 years) and supernormal vascular aging (Δ-age>6.8 years). The risk for fatal and nonfatal cardiovascular events associated with vascular aging categories was investigated in the Malmö Diet and Cancer Study cohort (n=2642). In the Malmö Diet and Cancer Study Cohort (6.6-year follow-up, 286 events), Δ-age was significantly (P<0.01) and inversely associated with cardiovascular events. Compared with normal vascular aging, supernormal vascular aging had lower risk (hazard ratio, 0.59 [95% CI, 0.41-0.85]), whereas early vascular aging had higher risk (hazard ratio, 2.70 [95% CI, 1.55-4.70]) of cardiovascular events, in particular coronary events. There was no significant association with all-cause mortality. This study represents the first validation of the clinical significance of the supernormal vascular aging concept, based on prospective data. Its further characterization may help discovering novel protective molecular pathways and providing preventive strategies for successful vascular aging.
Related Concept Videos
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension II: Pathophysiology
Coronary Artery Disease III: Clinical Manifestations
Pharmacodynamics in Geriatric Patients: Effects of Age
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

